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Abstract  31 
 32 
Many hundreds of thousands of people around the world are living with the long-term 33 
consequences of spinal cord injury and they need effective new therapies. Laboratory research in 34 
experimental animals has identified a large number of potentially translatable interventions but 35 
transition to the clinic is not straightforward. Further evidence of efficacy in more clinically-36 
relevant lesions is required to gain sufficient confidence to commence human clinical trials. Of the 37 
many therapeutic candidates currently available, intraspinally applied chondroitinase ABC has 38 
particularly well-documented efficacy in experimental animals. In this study we measured the 39 
effects of this intervention in a double-blinded randomized controlled trial in a cohort of dogs with 40 
naturally-occurring severe chronic spinal cord injuries that model the condition in humans. First, 41 
we collected baseline data on a series of outcomes: forelimb-hindlimb coordination (the pre-42 
specified primary outcome measure), skin sensitivity along the back, somatosensory evoked and 43 
transcranial magnetic motor evoked potentials and cystometry in 60 dogs with thoracolumbar 44 
lesions. Dogs were then randomized 1:1 to receive intraspinal injections of heat-stabilized, lipid 45 
microtube-embedded chondroitinase ABC or sham injections consisting of needle puncture of the 46 
skin. Outcome data were measured at 1, 3 and 6 months after intervention; skin sensitivity was 47 
also measured 24 hours after injection (or sham). Fore-hind coordination was affected by neither 48 
time nor chondroitinase treatment alone but there was a significant interaction between these 49 
variables such that coordination between forelimb and hindlimb stepping improved during the 6-50 
month follow-up period in the chondroitinase-treated animals by a mean of 23%, but did not 51 
change in controls. Three dogs (10%) in the chondroitinase group also recovered the ability to 52 
ambulate without assistance. Sensitivity of the dorsal skin increased at 24 hours after intervention 53 
in both groups but subsequently decreased to normal levels. Cystometry identified a non-54 
significant improvement of bladder compliance at 1 month in the chondroitinase-injected dogs but 55 
this did not persist. There were no overall differences between groups in detection of sensory 56 
evoked potentials. Our results strongly support a beneficial effect of intraspinal injection of 57 
chondroitinase ABC on spinal cord function in this highly clinically-relevant model of chronic 58 
severe spinal cord injury. There was no evidence of long-term adverse effects associated with this 59 
intervention. We therefore conclude that this study provides strong evidence in support of initiation 60 
of clinical trials of chondroitinase ABC in people with chronic spinal cord injury.       61 
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Introduction 66 
During the past two decades many interventions have successfully improved functional and 67 
histological outcome measures in animals with experimental spinal cord injury (Kwon et al., 2011; 68 
Tetzlaff et al., 2011). In contrast, this research has not yet delivered an indisputably effective 69 
treatment for human patients. Achievement of this underlying objective is impeded, in part at least, 70 
because the many differences between clinical spinal cord injury in humans and traditional 71 
experimental animal models mean that statistical improvement in a laboratory model does not 72 
imply that there will also be similarly meaningful benefit in clinical injuries (Kwon et al., 2015).  73 
 74 
Most critically, laboratory rats commonly used in spinal cord injury studies are young, genetically 75 
near-identical and their experimental injuries are homogenous in character and severity. Such 76 
homogeneity is desirable in the laboratory because it enables the signal of the investigated 77 
intervention to be discerned amongst the noise of other variables that might influence outcome. In 78 
contrast, human spinal cord injury patients and their injuries are highly heterogeneous - even 79 
within clinical sub-categories there is a great deal of variation in demographic features, co-80 
morbidities and outcome (Fawcett et al., 2007) - which means that the functional benefit that might 81 
be associated with a therapeutic intervention is less easily recognized. On the other hand, unless 82 
an intervention is sufficiently effective to make a substantial change in the lives of individual 83 
patients, for instance by altering their dependency on others for care, then it will not become 84 
adopted as a worthwhile clinical intervention.  85 
 86 
Pet dogs frequently suffer acute spinal cord injury (Moore et al., 2017) and these dogs undergo 87 
similar diagnostic, surgical and rehabilitation procedures to their human counterparts. Also similar 88 
to human patients, some will fail to recover with conventional therapy alone. This leaves a large 89 
population of chronically-injured dogs for which there is no available effective therapy and that 90 
can serve as a spontaneous model for testing therapies thought to have promise for translation from 91 
laboratory to clinic. Lesions in these dogs (Griffiths, 1972; Smith & Jeffery, 2006; Levine et al., 92 
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2011) closely model many features of chronic spinal cord injury in humans. Such a translational 93 
model is difficult to replicate in laboratory animals. 94 
 95 
There are many interventions that could be suitable for testing in this canine model of chronic 96 
spinal cord injury – specifically, those that have undergone repeated successful testing in 97 
experimental animals in multiple laboratories throughout the world. In this study we selected 98 
chondroitinase ABC, which has been demonstrated to improve outcome in numerous experiments 99 
on spinal cord-injured rodents (Bradbury et al., 2002; Bartus et al., 2014), cats (Jefferson et al., 100 
2011) and non-human primates (Bowes et al., 2012). Chondroitinase ABC is a bacterial enzyme 101 
that can digest the chondroitin sulfate proteoglycans that constitute a major part of the scar that 102 
forms in spinal cord lesions and blocks axonal regeneration (Bradbury and Carter, 2011). Current 103 
obstacles to translation of this agent into human spinal cord injury patients are: i) the need for a 104 
formulation with stability at mammalian body temperature so as to provide persistent activity 105 
without the need for repeated administration (see Bradbury and Carter, 2011);  and, ii) the need to 106 
demonstrate efficacy and safety in realistic translational models. The first obstacle can be 107 
overcome by buffering in trehalose and embedding in lipid microtubes which, together, render 108 
chondoitinase ABC heat-stable and long-acting (Lee et al., 2010). Here we addressed the second 109 
obstacle by conducting a randomized controlled clinical trial to measure the effects of lipid 110 
microtube-embedded chondroitinase ABC in dogs with severe chronic clinical spinal cord injury; 111 
this could be considered a final prelude to commencement of formal regulatory approval processes 112 
for translation into similarly-injured humans. 113 
 114 
 115 
Materials and methods  116 
Methods        117 
The study design, primary and secondary outcomes measures and analytical methods were all pre-118 
specified and carried out in accordance with the submitted funding proposal (held by the sponsor, 119 
the International Spinal Research Trust). The pre-specified primary outcome measure was a 120 
measure of temporal coordination between forelimb and hindlimb motion that we have previously 121 
described (Hamilton et al., 2007); further details of the methods are available below and in 122 
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Supplementary Material. All procedures and the trial design were approved by the Institutional 123 
Animal Care and Use Committee at Iowa State University (Log number: 3-13-7526-K).   124 
 125 
Animals 126 
We aimed to recruit a sample size of 60 (see sample size calculations below) dogs weighing less 127 
than 20 kg and with chronic severe spinal cord injury confined between T3 and L3 vertebrae; dogs 128 
have 13 thoracic and 7 lumbar vertebrae. For inclusion, dogs had to have persistent loss of urinary 129 
continence and voluntary motor function in the hindlimbs following an acute spinal cord injury 130 
occurring at least 3 months before recruitment. Most of these dogs had suffered acute intervertebral 131 
disc herniation, which is common in small dogs (Moore et al., 2017). Typical cases had no 132 
voluntary motor function in the hindlimbs, no discernible sensory function to any part of the 133 
hindquarters (including the tail) and were both urinary and fecally incontinent. Dogs were 134 
excluded from the study if they had lesions affecting the lumbosacral intumescence (L4 to S3 135 
spinal cord segments), had concurrent orthopedic disorders that would preclude recovery of 136 
walking, or had any condition from which they were expected to die within 1 year. Dogs that were 137 
too aggressive or anxious to be controlled when they walked on a treadmill were excluded.  138 
 139 
Materials 140 
Preparation of chondroitinase ABC 141 
Chondroitinase ABC was obtained from a commercial supplier (AMSBIO) as a lyophilized 142 
powder in a sterile ampoule (see Supplementary Material). The powder was reconstituted in filter-143 
sterilized 38% trehalose solution (10 Units per 1600 L trehalose solution), which was divided 144 
into 400 L aliquots that were kept frozen at -80 oC until mixed with the lipid microtubes. The 145 
lipid microtubes were prepared according to the previously published protocol (Lee et al., 2010; 146 
see Supplementary Material). On the day before intraspinal injection, a stock 400 L aliquot of 147 
reconstituted chondroitinase ABC in 38% trehalose was thawed and mixed with one batch of 148 
microtubes until it formed a homogenous milky suspension; this was then stored overnight at 4 oC 149 
to allow adsorption of the chondroitinase ABC solution onto the microtubes. Each dog received 150 
200 L of the trehalose/microtube suspension re-diluted in a further 200 L of 38% trehalose 151 
solution immediately before it was injected into the spinal cord. The total 400 L suspension 152 
(containing 1.25 Units of chondroitinase) was divided into an injection of 200 L (625 mU) at 153 
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each injected site; each of these injections was administered in two aliquots, with the needle bevel 154 
facing caudally and cranially respectively (see below). The dose was selected based on ‘scaling 155 
up’ calculations from rodent experiments as described in Supplementary Material.       156 
 157 
Procedures   158 
Pre-study 159 
Each dog underwent neurological examination to confirm the site and severity of the lesion. This 160 
included routine examination of the level of the injury through assessment of the cutaneous trunci 161 
muscle reflex (Gutierrez-Quintana et al., 2012). After the neurologic examination and obtaining 162 
written informed consent from the owners, dogs were formally admitted to the trial.  163 
 164 
Each dog then underwent a series of baseline functional tests, including analysis of coordination 165 
of gait during treadmill walking, von Frey filament testing of skin sensitivity, cystometry and 166 
electrophysiological recordings. On the fourth day of hospitalization each dog was randomized to 167 
receive either a percutaneous intraspinal injection of chondroitinase ABC or to undergo needle 168 
puncture of the dorsal skin (so as to blind the observer and owner regarding treatment allocation). 169 
Allocation was equal between groups and determined by opening the next in a numbered series of 170 
sealed opaque envelopes each containing a slip of paper labeled ‘ChAse’ or ‘Control’. These were 171 
prepared in batches of 20; the batching method was not known to the observer who recorded the 172 
functional outcomes. 173 
 174 
Study procedures 175 
Treadmill gait recordings were made similarly to previous reports (Hamilton et al., 2007; 176 
Granger et al., 2012). Briefly, each dog was walked at constant speed on a treadmill while held on 177 
a leash. The hindquarters were supported by a sling placed under the abdomen to maintain the 178 
vertebral column in a normal walking position parallel to the treadmill belt. Reflective markers 179 
were placed on the lateral aspect of each paw and both elbows and their motion was recorded by 180 
the Vicon infra-red motion analysis system. The primary outcome measure was temporal 181 
coordination between each fore paw and the contralateral hind paw strike (i.e. diagonal coupling). 182 
The mean value for coupling of both right and left forelimbs with their diagonal pairs was used for 183 
the final statistical analysis. More details are provided in Supplementary Material.  184 
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 185 
Von Frey filaments assessed skin sensitivity before and after chondroitinase ABC injection or 186 
sham treatment. At each time point the von Frey filaments were applied to the skin on both sides 187 
of the dorsal aspect of each dog starting at the level of L6 vertebra and progressing cranially in 188 
steps corresponding to the length of one vertebra up to the scapulae (the region of T6 vertebra). A 189 
positive response was defined as a behavioral response suggestive of cranial perception of the 190 
stimulus (whether noxious or non-noxious). The sum total number of positive responses at each 191 
time point was used for analysis.  192 
 193 
Cystometry was used similarly to a previous report (Granger et al., 2012) to determine the 194 
compliance of the bladder during filling with room-temperature sterile 0.9% saline solution as is 195 
routine in human patients (Biering- Sørensen  et al., 2008). Briefly, the bladder was catheterized 196 
and then filled at a rate of 10 mL/minute for dogs <10 kg and 20 mL/min for dogs >10 kg, while 197 
measuring the bladder pressure. The end-point was detrusor contraction and (partial) bladder 198 
voiding or an intravesicular pressure of 40 cmH2O (because pressures higher than this can risk 199 
damage to the ureters and kidneys).  200 
 201 
Transcranial magnetic evoked motor potentials were obtained with dogs under sedation with 202 
butorphanol (0.2 mg/kg) and dexmedetomidine (5 g/kg), as described previously (Sylvestre et 203 
al., 1993; da Costa et al., 2006; Granger et al., 2012). Briefly, a 90 mm single coil powered by a 204 
current generator (Magstim 200, Wales, UK) was positioned tangentially over the skull (lateral 205 
and rostral to the vertex and 2 cm from midline) and discharged at 80% maximum power (~2 T on 206 
the skull surface, see Nollet et al., 2003) while recording the latencies of the evoked compound 207 
muscle action potentials in the cranial tibialis and extensor carpi radialis muscles using concentric 208 
recording needles. [The extensor carpi radialis was used as a control for the sedation level because 209 
excessive sedation can eliminate this motor potential in normal limbs.] The test was repeated three 210 
times for each hindlimb (i.e. stimulation was directed at each side of the brain in turn) after we had 211 
obtained a positive response from the forelimb. We recorded the latency and amplitude of the last 212 
wave of the series; only waves of amplitude greater than 0.15 mV were considered a positive 213 
response.   214 
 215 
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Sensory evoked potentials were recorded using a monopolar needle electrode placed 216 
percutaneously to lie on the laminae of the thoracolumbar vertebrae or the interarcuate ligament, 217 
during stimulation of the tibial nerve just proximal to the hock (ankle) joint, with the subcutaneous 218 
reference electrode placed ~2 cm laterally, as previously described (Poncelet et al., 1993). The 219 
stimulus intensity was set to be just sufficient to evoke an observable response in the distal 220 
musculature. We recorded the latency and amplitude of this wave at each vertebral level from L5 221 
moving cranially until a response could not be detected. Sensory evoked potentials were 222 
designated as ‘intact’ if the same waveform, with a peak-to-peak amplitude of >0.15 V could be 223 
repeated at least once during signal averaging of at least 200 sweeps. Each tibial nerve were 224 
stimulated and recorded individually and the site of the most cranial intact response was used for 225 
subsequent analysis.     226 
 227 
Intraspinal injection 228 
Under general anesthesia each dog was positioned for fluoroscopy in right lateral recumbency so 229 
that one 22 Gauge, 1.5 or 2.5 inch, spinal needle could be placed into the lesion epicenter and 230 
another spinal needle placed into the spinal cord at the L3/4 vertebral interspace (the cranial margin 231 
of the spinal cord segments containing the lower motor neurons of the central pattern generator for 232 
the hindlimbs). If the primary lesion was at L3/4 then the L4/5 site was also injected. Each needle 233 
was initially placed midline into the subarachnoid space so that cerebrospinal fluid flowed from 234 
the hub and then repositioned so that the bevel would lie within the spinal cord parenchyma. 235 
Injections were made using a 1 mL Luer lock syringe with the needle bevel in the center of the 236 
spinal cord parenchyma - a depth of approximately 3 mm from the dorsal dura. A total of 200 L 237 
chondroitinase preparation, divided into two aliquots, was injected at each site; one aliquot was 238 
injected with the bevel facing cranially and one with it facing caudally. Each 100 Laliquot 239 
injection was timed to be completed within at least 120 seconds. The volume of injection is 240 
discussed in Supplementary Material. 241 
 242 
Follow-up protocol 243 
The functional tests were repeated by an observer blinded to treatment allocation at 1, 3 and 6 244 
months after injection of chondroitinase (or skin puncture control); von Frey filament testing was 245 
also repeated at 24 hours after intervention. At each re-visit, each owner was interviewed with a 246 
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specific set of questions about changes in their dog’s general health, behavior, locomotor and 247 
bladder function and then each dog stayed in the clinic for 5 days. During this period each dog 248 
underwent the functional tests described above and also received 30-60 minutes daily physical 249 
therapy tailored to their individual needs by a certified canine rehabilitation technician who was 250 
blinded to their treatment category. Briefly, exercises consisted of swimming, underwater 251 
treadmill walking, sit-to-stand repetition, weight shifting, balancing exercises and encouragement 252 
to walk with hindquarter support using slings and carts. Owners were instructed to continue 253 
appropriate physical therapy at home and encourage dogs to ambulate in their home environment. 254 
Urination in these incontinent dogs was managed at home and in the clinic by manual compression 255 
of the caudal abdomen to trigger reflex urination. Owners were instructed to express urine as fully 256 
as possible at least three times daily.    257 
 258 
Owners remained blinded to treatment allocation group of their dogs until after collection of all 259 
follow-up outcome measurements and completion of their final interview.       260 
 261 
Statistics 262 
Sample size calculation 263 
We estimated the need for 24 dogs in each group to detect a 25% difference in the primary outcome 264 
measure at 6 months after intervention with power of 80% and of 0.05. Because dropout was 265 
expected in this type of trial (death from complications of paraplegia, owners unable to travel, etc) 266 
we aimed to recruit 30 dogs in each group.  267 
 268 
Codes were broken after completion of all data collection, including owner interviews, and 269 
checking to ensure data completeness (bearing in mind missed data points through bad weather, 270 
owner withdrawal etc) and after processing to provide data on primary outcome temporal 271 
relationships. Raw primary outcome data was analyzed by an investigator who had no knowledge 272 
of treatment group and supplied processed data that summarized diagonal coupling relationships 273 
to another investigator who carried out the statistical analysis.  274 
 275 
Data analysis: For all outcomes, data were assessed for Gaussian distribution and then 276 
transformed, if necessary, using Box-Cox analysis and the ‘gladder’ command to determine 277 
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suitable transformation using Stata 11 for Windows (StataCorp, College Station, TX, USA). The 278 
primary outcome data were analyzed with a multilevel linear regression model (‘xtmixed’) using 279 
Stata 11, using random effects for subjects and fixed effects for the intervention and including a 280 
term for interaction between chondroitinase and time, whilst adjusting for baseline measurements 281 
by their inclusion as a covariate. Standard post hoc commands (‘contrast’) in Stata were used to 282 
determine main effects and to further explore interactions.  Similar analyses were applied to the 283 
bladder compliance data. The remaining outcomes data were plotted to check distributions and 284 
pre- and post-intervention values compared using paired Student’s t tests or equivalent non-285 
parametric analyses. P < 0.05 was taken to indicate a significant relationship between dependent 286 
and independent variables or differences between the control and active intervention 287 
(chondroitinase ABC) groups. 288 
 289 
Sensitivity of the primary outcome analysis to data lost to follow-up was assessed through two 290 
secondary analyses: i) inclusion of only those animals for which there was a complete dataset; and, 291 
ii) derivation of a more complete dataset by multiple imputation in Stata (see Supplementary 292 
Material).   293 
 294 
 295 
Results 296 
A total of 60 dogs was recruited and randomly allocated between the intervention and control 297 
groups in a 1:1 ratio as planned (Fig.1; Table 1; Table 2). As explained in Supplementary Material, 298 
dogs with severe chronic spinal cord injury sometimes develop a pattern of so-called ‘spinal 299 
walking’ (Gallucci et al., 2017) and this was noted at enrolment in 5/30 dogs allocated to the 300 
chondroitinase group and 4/30 dogs in the control group.      301 
 302 
Primary outcome measure 303 
Treadmill locomotion 304 
Plots summarizing the ‘before’ and ‘after’ values for the control and intervention groups suggested 305 
improvement associated with intraspinal chondroitinase injection (Fig. 2). Corresponding 306 
summary statistics reveal a 23% improvement (i.e. a reduction in numerical score) in mean 307 
coordination score from baseline to the 6-month follow-up in the chondroitinase group (from 2.16 308 
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to 1.67; paired Student’s t test P = 0.008) whereas in the control group there was a 2% deterioration 309 
in mean score (1.99 to 2.03; paired Student’s t test P = 0.677). Graphs of coordination against time 310 
at a group level revealed this change to be a gradual restoration, in the chondroitinase-injected 311 
group only, of a more normal temporal association of forelimb and hindlimb stepping as time 312 
elapsed (Fig. 2). At the start of the trial, control and chondroitinase groups exhibited similar 313 
dysfunction but, with increasing length of follow-up, the chondroitinase group regained 314 
progressively better function, whereas the control group did not, commensurate with significant 315 
interaction between chondroitinase and time. Multilevel modeling and post hoc analysis revealed 316 
that there was no overall effect of either time (2 = 4.91; P = 0.178) or chondroitinase injection (2 317 
= 1.69; P = 0.194) alone following the intervention but a significant interaction between these two 318 
variables (2 = 9.17; P = 0.027). Specifically, coordination in chondroitinase-injected dogs at 6 319 
months was significantly improved compared to their baseline (= -0.555; 95%CI: -0.956/-0.155; 320 
P = 0.007) and compared to coordination in control animals at 6 months (= -0.484; 95%CI: -321 
0.790/-0.178; P = 0.002) (Supplementary Material, Tables 1 and 2 show complete model results).  322 
 323 
Together with the effect of chondroitinase to improve coordination in the recipient group overall, 324 
three dogs (of 27 available for follow-up at 6 months) in the chondroitinase group regained the 325 
ability to walk unaided, but this occurred in none (of 25 available at 6 months) of the controls 326 
(Fisher’s exact test P = 0.236). All three of these individuals recovered the ability to walk by 1 327 
month and this persisted throughout the remainder of the study; between baseline and 6 months 328 
one showed better coordination and two worse coordination (pre-post scores were: 2.10-1.06, 329 
2.64-2.85, 1.96-2.59 respectively). In Figure 2b two dogs show 6-month post-chondroitinase 330 
coordination scores approaching zero (i.e. near-normal). One of these dogs was able to weakly 331 
ambulate at the commencement of the study (one of the five in the group showing ‘spinal walking’, 332 
with a coordination score of 2.08) but improved following the intervention; the other dog (with an 333 
entry score of 2.39) did not recover the ability to ambulate independently during the 6-month study 334 
period but limb movements were described as ‘stronger’ by the owner.      335 
 336 
All dogs included in this study received the treatment to which they were randomly allocated 337 
meaning that intention-to-treat and per protocol analyses would not differ. However, we wished 338 
to determine whether the results may have been influenced by missing data points and so we 339 
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carried out two further analyses: first, including only dogs for which we had complete datasets and 340 
the second on data for which missing values had been imputed (see Material and Methods and 341 
Supplementary Material). The results of both these analyses were similar to those of the original 342 
analysis (see above), confirming the combinatorial effect of chondroitinase injection and time in 343 
improving coordination at 6 months (with respect to baseline) in the chondroitinase group 344 
(compete datasets: = -0.594; 95%CI: -0.1.04/-0.151; P = 0.009; multiple imputation dataset: = 345 
-0.518; 95%CI: -0.917/-0.118; P = 0.011) and also providing confidence that this outcome was not 346 
biased by missing data.        347 
 348 
Secondary outcome measures 349 
Von Frey filament testing of skin sensitivity 350 
Responses were highly variable between individuals but the median score was zero responses in 351 
both groups at all time points. At 24 hours after intervention, both control and chondroitinase-352 
injected dogs showed similar increase in responses but this rapidly regressed and remained 353 
comparable between groups at both 3 and 6 months after intervention (Fig. 3). Statistical analysis 354 
revealed no evidence for a differentially detrimental effect of injection of the chondroitinase ABC 355 
preparation compared with the sham-treated animals (Mann-Whitney test pre-post scores: P = 356 
0.671) and no owners in either group reported evidence for pain behavior at any follow-up 357 
interview. More detailed assessment of individual animal data is provided in Supplementary 358 
Material.  359 
 360 
Bladder compliance   361 
At baseline, compliance was highly variable in both groups, ranging from 0.7-180 mL/cmH2O in 362 
the chondroitinase group and 0.96-150 mL/cmH2O in the control group, with medians of 4.8 and 363 
4.6 respectively (the reference interval is not well-established in dogs but thought likely to be 364 
similar to that in humans, i.e. ~12-40mL/cmH2O [Toppercer and Tetreault, 1979; Combrisson & 365 
Cotard, 1989; Harris et al., 1996]). Overall, there appeared to be a differing pattern of change after 366 
the interventions, with a tendency for compliance to increase in the chondroitinase group and 367 
decrease in the control group at the 1 month re-examination (Fig. 4). Examination of individual 368 
animal responses suggested that compliance increased in more dogs in the chondroitinase group 369 
than in the control group, with substantial increases occurring in a small minority of dogs in both 370 
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groups (Fig. 4). In dogs with abnormally low compliance (<12.5 mL/cmH2O) there was an increase 371 
to within reference interval in 1/28 of control cases at the 1-month follow-up; a similar change 372 
occurred in 2/27 chondroitinase-injected dogs. The apparent difference between groups at 1 month 373 
did not persist and by 6 months after injection compliance in both groups had returned to values 374 
that were similar to those at baseline. Statistical analysis indicated that, even when controlled for 375 
the possible confounding effect of the duration of paralysis in each dog, neither the overall effect 376 
of injection of the chondroitinase ABC preparation (= 0.028; 95%CI: -0.643/0.691; P = 0.933), 377 
nor its specific effect at 1 month follow-up (= 0.600; 95%CI: -0.120/1.32; P = 0.103) had a 378 
significant association with compliance. 379 
 380 
Transcranial magnetic motor evoked potentials 381 
At entry to the trial, 3/30 control dogs and 3/30 dogs allocated to receive chondroitinase exhibited 382 
recordable transcranial magnetic motor evoked potentials in at least one cranialis tibialis muscle. 383 
One of the control dogs also exhibited so-called spinal walking but the other five (two controls 384 
and three chondroitinase-treated dogs) did not. During follow-up, transcranial magnetic motor 385 
evoked potentials continued to be recorded from similar numbers of dogs in both control and 386 
chondroitinase groups concluding with positive responses elicited from 3/25 controls and 4/27 387 
chondroitinase dogs at 6 months.         388 
 389 
transcranial magnetic motor evoked potentials were recorded de novo during the trial in two dogs 390 
in the chondroitinase group that also recovered independent ambulation (see above) and were also 391 
recorded during the trial in a third chondroitinase-injected dog, in which the fore-hind coordination 392 
score returned almost to normal values at 6 months. Positive transcranial magnetic motor evoked 393 
potential recordings at some, but not all, follow-up examinations were also noted in three dogs in 394 
the control group, two of which showed spinal walking at entry to the trial.   395 
 396 
Sensory evoked potentials 397 
In the control group there were 21 animals with pre- and post-intervention percutaneous sensory 398 
evoked potential recordings and 22 in the chondroitinase group but there appeared to be no 399 
difference between groups in change in cranial-caudal level of response (Fig. 5; Mann Whitney 400 
test: P = 0.926).  401 
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 402 
Assessment of adverse events 403 
Over the entire follow-up period owners reported a total of 19 adverse events that they associated 404 
with the periods when dogs stayed in the hospital during which interventions, tests of outcome and 405 
physical therapy were given: 11 occurred in the chondrotinase group and 8 in the controls. These 406 
reported adverse events were all transient, lasting for up to 3 days; the majority were periods of 407 
diarrhea, evidence of urinary tract inflammation or infection or, on three occasions, reduced 408 
activity for 1-3 days.   409 
 410 
Adverse events noted by the owners after the first visit - during which baseline functional data 411 
were collected and the intervention applied - included eight events in chondroitinase dogs and one 412 
in a control animal. Three dogs that had received chondroitinase showed reduction in mobility that 413 
lasted for up to 3 days (two of these dogs subsequently recovered independent ambulation) and 414 
one additional dog appeared painful for the first 12 hours after injection. Two chondroitinase-415 
injected dogs showed evidence of urinary tract infections and one had a generalized seizure 416 
immediately upon recovery from anesthesia. One chondroitinase-injected and one control dog 417 
developed diarrhea during hospitalization.   418 
 419 
At the 1-month re-examination, five adverse events were noted: two episodes of diarrhea (one in 420 
each group), two dogs had skin lesions overlying bony prominences of the pelvis (one in each 421 
group) and one dog (chondroitinase-injected) showed periods of spasmodic limb muscle activity 422 
for a week following this visit. Five further adverse events (four of lower urinary signs and one of 423 
diarrhea) in control animals were recorded during the following two re-visits. None of the owners 424 
reported evidence of abnormal sensitivity on their dogs (e.g. flinching, crying, whining or biting 425 
when being touched) at any stage throughout the study.         426 
 427 
 428 
Discussion   429 
The results of this study confirm that intraspinal injection of heat-stabilized chondrotinase 430 
improves locomotor function in this chronic, severe, naturally-occurring model that mimics 431 
clinical spinal cord injury in humans. Importantly, the effect became increasingly prominent with 432 
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increasing time after injection, during which dogs received tailored physical therapy, supporting a 433 
previous intimation that chondroitinase and directed physical activity are synergistic in restoration 434 
of spinal cord function (Garcia-Alias et al., 2009). In addition, while at home the dogs were 435 
encouraged to move around their home environment, which may have played a role similar to that 436 
of an enriched environment for spinal cord-injured rats (Lankhorst et al., 2001). Such formal and 437 
voluntary physical therapy might contribute to the strong response in this outcome in the 438 
chondroitinase-injected dogs.  439 
 440 
Interestingly, it appears that we detected two types of recovery of locomotor activity associated 441 
with intraspinal chondroitinase injection. First, there was widespread improvement in fore-hind 442 
coordination throughout the group as a whole, with two dogs recovering near-normal values (see 443 
Fig. 2). In addition three dogs developed independent locomotion that was not associated with 444 
improved fore-hind coordination. We consider that each type of response could be associated with 445 
activity of the chondroitinase at either one or both injection sites. First, improvement of 446 
coordination implies transmission of impulses across the lesion site (so that fore and hind limbs 447 
become temporally coordinated) and can be explained either by regeneration of axons across the 448 
lesion site (Bradbury et al., 2002; Yick et al., 2003; Barritt et al., 2006) or restoration of 449 
functionality to pre-existing fibers through chondrotinase-mediated effects on the damaged tissue 450 
(for instance via release of matrix-bound factors [Crespo et al., 2007]). Such effects may or may 451 
not also require reorganization of targets in the destination tissue that may have been facilitated by 452 
the more caudal chondroitinase injection. We propose that this mechanism of action explains the 453 
increased coordination noted within the group as a whole, and especially in the two dogs whose 454 
coordination scores improved to near-normal values (and one of which also showed recovery of 455 
recordable transcranial magnetic motor evoked potentials). In contrast, in some animals - perhaps 456 
those in which axon regeneration or restoration of functionality across the lesion site was not 457 
feasible because of its character or severity - chondroitinase effects at the more caudal injection 458 
site may have been sufficient to allow reorganization of synaptic contacts, via disruption of 459 
perineuronal nets (Massey et al., 2006; Cafferty et al., 2008; Garcia-Alias et al., 2009), thus 460 
facilitating development of ‘spinal walking’. We propose that this mechanism may underlie the 461 
recovery of independent locomotion in the three dogs that did not exhibit improved coordination; 462 
however, there is a need for further examination of this possible effect since few chondroitinase-463 
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injected dogs recovered in this way and there was not a significant difference in its incidence 464 
between control and chondroitinase groups.     465 
   466 
The absence of evidence to suggest that intraspinal chondroitinase injections caused problematic 467 
adverse effects is of critical importance. A particularly worrisome aspect of any intervention that 468 
involves intraspinal administration of an agent that might induce plastic change in the nervous 469 
system is that it might also engender abnormal pain sensation, especially in the dermatomes of the 470 
injected region. The data we collected here on responses to von Frey filament stimulation over the 471 
dorsum are consistent with development of hypersensitivity in the immediate post-intervention 472 
period. However, there was a similar incidence of increased sensitivity in both chondroitinase and 473 
control dogs, providing strong evidence that the chondroitinase injection was not the cause. 474 
Instead, heightened sensitivity is better attributed to the combination of hair clipping and needle 475 
damage to the skin, which were factors common to both groups. During the remainder of the 476 
follow-up period skin sensitivity gradually decreased in both groups to that observed at enrolment.   477 
 478 
Owners were encouraged, through specific interview questions, to report any adverse events 479 
following recruitment into the trial. Although many events were reported, these occurred at similar 480 
frequency in both control and chondroitinase groups. Furthermore, most of the adverse events were 481 
suggestive of non-specific effects of staying in our hospital or undergoing the investigative 482 
procedures. For instance, diarrhea is very common in dogs after periods of stress, and urinary tract 483 
irritation or infection can be associated with cystometry. One dog that had been injected with 484 
chondroitinase exhibited seizures upon recovery from anesthesia. Although this might appear 485 
rather alarming, it is unlikely that this was a consequence of the intraspinal injections. First, the 486 
volume of the injections was very small, meaning that it would be highly improbable for the 487 
injected material to reach the brain via the cerebrospinal fluid. Second, this dog may have been at 488 
inherent increased risk of seizures because the spinal cord injury was the result of a fracture-489 
luxation at L1/2 vertebrae and head injury is common correlate of spinal fractures in dogs. This 490 
dog recovered uneventfully and showed no persistent abnormalities of brain function or repeat 491 
seizures during the follow-up period.    492 
 493 
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The compliance results recorded at the 1-month follow-up provide a slight suggestion that 494 
chondroitinase injection might open an opportunity for improving bladder function. The group of 495 
chondroitinase-injected dogs as a whole demonstrated much higher compliance (i.e. ability to 496 
retain more urine) at the first follow-up assessment. However, this effect was not statistically 497 
significant and faded by the time of later re-assessments. It is possible that the initial change in 498 
function could have been an effect of chondroitinase that did not persist and it might be that more 499 
effective or prolonged training of bladder function might make this improvement more permanent. 500 
However, while the group effects look promising, analysis at an individual level (Fig. 4) suggests 501 
that normal bladder compliance (estimated as 12-40 mL/cmH2O) was restored in few dogs in either 502 
group at this time point. Whilst it remains possible that chondroitinase may have a beneficial effect 503 
on bladder function there was such a large degree of variability in compliance at enrolment that 504 
detecting such an effect may be difficult unless trial participants are stratified for this variable.      505 
 506 
At a group level, there were no readily attributable effects of chondroitinase ABC on the secondary 507 
electrophysiological outcome measurements, which were designed to provide possible 508 
explanations for any changes in overall function that we detected in the primary analysis. This lack 509 
of change parallels the findings of our previous study on olfactory ensheathing cell transplantation 510 
(Granger et al., 2012). There are two main possible explanations. First, the changes that occur in 511 
the spinal cord to mediate improvement in limb girdle coordination do not necessarily rely on 512 
changes in spinal cord long tract function. For instance, changes in propriospinal connections may 513 
improve fore-hind coordination but will not be detected by the evoked potential recordings that 514 
are dependent upon long tract integrity. The second possible explanation is that these measures of 515 
long tract function are not sufficiently sensitive to detect changes that were elicited by the 516 
chondroitinase injection. Evidence in support of this proposition is that chronic, histologically sub-517 
complete spinal cord injury in rats can abolish motor evoked potentials (Metz et al., 2000) and it 518 
is known that, after acute spinal cord injury, transcranial magnetic motor evoked potentials can 519 
even be abolished in dogs with purposeful movement (Sylvestre et al., 1993). Moreover, although 520 
there is a general (inverse) correlation between latency of evoked potentials and white matter 521 
preservation (Nashmi et al., 1997), the precise relationship between intact detected conduction and 522 
the number of intact axons is unknown. Despite these limitations, in the five dogs that showed 523 
recovery of independent ambulation (n = 3) or recovery of normal fore-hind coordination (n = 2), 524 
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transcranial magnetic motor evoked potentials could be recorded at some stage throughout the 525 
follow-up period.       526 
    527 
There has long been vigorous debate about how much pre-clinical evidence is required before it is 528 
reasonable to translate a successful intervention from the laboratory to humans with spinal cord 529 
injury (Kwon et al, 2013; Kwon et al., 2015). The evidence we present here suggests that 530 
chondroitinase ABC is at this threshold: not only has its beneficial effect been demonstrated 531 
repeatedly in laboratory animals but, as we show here, it is sufficiently potent to ameliorate lost 532 
function following severe clinical injury in a large mammalian species and it is not associated with 533 
detectable detrimental effects, which should all augur well for clinical benefit in humans with 534 
spinal cord injury. The question then remains as to whether the effect size is of sufficient 535 
magnitude to be of benefit were the therapy to be translated into humans. The change we detected 536 
in the primary outcome measure was ~23%, which can be regarded as a large treatment effect, 537 
corresponding to our ability to detect this difference in a reasonably-powered (80%) study, even 538 
in such a relatively small sample population. It is also of similar magnitude to that reported in a 539 
meta-analysis of olfactory ensheathing cell transplantation in experimental animals that was 540 
recommended as supportive evidence to pursue human clinical trials (Watzlawick et al., 2016). 541 
However, whether an intervention will translate from one species to another with the same 542 
magnitude of effect is almost impossible to predict, because the mechanisms of recovery may or 543 
may not translate between species. For instance, it is difficult to know whether the mechanisms 544 
underlying recovery of coordination in our dogs (or, similarly, recovery of open-field ambulation 545 
or forelimb reaching tasks in rats) will also lead to, for example, improved hand function in 546 
humans. The most plausible means to test the translatability is to trial the intervention in humans. 547 
Therefore the key value of our data is the detection of benefit in the face of real-life lesion 548 
heterogeneity and the absence of detectable adverse effects, because this combination provides a 549 
clear green light for the trials in humans that are necessary to categorically define the magnitude 550 
of effect in that species.  551 
 552 
A further question might be whether the drug preparation and delivery system we used here is the 553 
most clinically appropriate. Although there is evidence of persistence of effect of native 554 
chondroitinase ABC for at least 10 days after injection into the brain (Lin et al., 2008), the 555 
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consensus of opinion, summarized by Bradbury and Carter (2008), is that a translatable long-acting 556 
form of the enzyme is likely to be required for therapy of spinal cord injury. The composite product 557 
used in this study stabilizes the chondroitinase ABC active ingredient, facilitates sustained delivery 558 
and is easily delivered, therefore fulfilling this requirement. For the next step of introduction into 559 
humans and getting approval for clinical trial from regulatory agencies, the preparation will need 560 
to be made under appropriately controlled aseptic conditions. There do not appear to be any 561 
obstacles to this process: the lipid backbone used in the manufacture of the microtubes can be 562 
made under Good Laboratory Practice conditions and has already been used in a human clinical 563 
trial (Wicki et al., 2015). Percutaneous injection of chondroitinase was selected in this study 564 
because it readily permits blinding of study observers and owners of the participating dogs, but it 565 
may not be the optimal method of ensuring that the drug reaches its target. Open surgery would 566 
ensure delivery into precise locations within spinal cord parenchyma and could easily be applied 567 
in phase I trials in humans, but similar delivery in a phase II trial would necessitate sham surgery 568 
for controls, which can be ethically controversial (Albin, 2002; Frank et al., 2008). However, 569 
because participants in such a clinical trial would have chronic lesions with static neurologic 570 
function, a crossover design, similar to that proposed for cell transplantation for multiple sclerosis 571 
(Freedman et al., 2010), would be feasible. Although this would not avoid the need for sham 572 
surgery it would reduce the number of participants required and assure those recruited that, unless 573 
unforeseen safety issues arose, they would each receive the active intervention (chondroitinase).       574 
 575 
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 587 
Figure legends 588 
 589 
Figure 1: Flowchart showing how dogs were recruited to this trial. 60 dogs were randomized to 590 
chondroitinase ABC injection or control groups from a total pool of 196 possible candidate cases.   591 
 592 
Figure 2:  Trial primary outcome measure: coordination between fore and hind limb stepping in 593 
treadmill walking dogs before and after intervention. The score (on the y-axis) is a summary of 594 
accumulated time delays between forelimb and hindlimb steps, with lower scores indicating better 595 
coordination. a: individual records for control animals; b: individual records for chondroitinase-596 
injected animals; c: group summary over time (symbols represent mean and bars are standard error 597 
of the mean). Controls are illustrated in red and chondroitinase animals in blue. In control animals, 598 
although there is some (expected) intra-animal variability there is no systematic change over the 599 
6-month follow-up period (paired Student’s t test, P = 0.677). In contrast, both individual records 600 
(b) and group summary (c) of chondroitinase-injected animals show systematic and progressive 601 
reduction in score corresponding to improved coordination. At 6 months chondroitinase-injected 602 
animals improved by a mean of 23% from baseline (paired Student’s t test, P = 0.008) and was the 603 
result of a significant interaction between chondroitinase injection and time (see text); there was a 604 
significant difference between groups at 6 months (contrast = -0.484; 95%CI: -0.790 / -0.178; P = 605 
0.002).          606 
 607 
Figure 3: Summary of responses to von Frey filament stimulation, in which a higher score 608 
indicates greater sensitivity (symbols represent mean and bars are standard error of the mean). 609 
From a low baseline there is an increase in sensitivity on the day immediately after the intervention 610 
in both groups (chondroitinase injection or sham) that decreases over time. The lack of difference 611 
in scores between groups (Mann-Whitney test at 6 months P=0.107) and lower scores in the active 612 
treatment group indicate that there is no evidence for induction of neuropathic pain following 613 
chondroitinase injection.  614 
 615 
Figure 4: Change in bladder compliance after intervention. a: changes in group means (bars 616 
indicate standard error of the mean) over the 6-month follow-up period. In chondroitinase-injected 617 
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dogs there is an apparent increase in compliance (improved ability to retain urine) at 1 month but 618 
this does not persist; statistical comparisons detect no difference between groups at any point. 619 
b and c are spaghetti plots illustrating change in compliance over the first month after intervention 620 
in (b) control and (c) chondroitinase-injected dogs. Although there was a tendency for a greater 621 
proportion of dogs in the control group to show decreased compliance and a greater proportion of 622 
dogs in the chondroitinase group to show increased compliance in the first month, accounting for 623 
the changes observed in a, few animals in either group improved from abnormally low values to 624 
achieve values within the reference interval (indicated by dashed lines) at 1 month.     625 
 626 
Figure 5: Changes in cranial-most level of recording of spinal sensory-evoked potentials (SEP) in 627 
control and chondrotinase-injected dogs during the 6-month follow-up period. Although there was 628 
some individual variation in level at which the SEP could be recorded as the study progressed there 629 
was no indication of a systematic difference in this variable between treatment groups.   630 
 631 
 632 
References  633 
 634 
Albin RL. Sham surgery controls: intracerebral grafting of fetal tissue for Parkinson's disease and 635 
proposed criteria for use of sham surgery controls. 636 
J Med Ethics 2002; 28: 322-5. 637 
 638 
Barritt AW, Davies M, Marchand F, Hartley R, Grist J, Yip P, McMahon SB, Bradbury EJ. 639 
Chondroitinase ABC promotes sprouting of intact and injured spinal systems after spinal cord 640 
injury. J. Neurosci 2006; 26: 10856-10867. 641 
 642 
Bartus K,  James ND, Didangelos A, Bosch KD, Verhaagen J, Yáñez-Muñoz RJ, et al. Large-scale 643 
chondroitin sulfate proteoglycan digestion with chondroitinase gene therapy leads to reduced 644 
pathology and modulates macrophage phenotype following spinal cord contusion injury. J 645 
Neurosci 2014; 34: 4822-36. 646 
 647 
22 
 
Biering-Sørensen F, Craggs M, Kennelly M, Schick E, Wyndaele JJ. International urodynamic 648 
basic spinal cord injury data set. Spinal Cord 2008; 46: 513–6. 649 
 650 
Bowes C, Massey JM, Burish M, Cerkevich CM, Kaas JH. Chondroitinase ABC promotes 651 
selective reactivation of somatosensory cortex in squirrel monkeys after a cervical dorsal column 652 
lesion. Proc Natl Acad Sci U S A 2012; 109: 2595-600.  653 
 654 
Bradbury EJ, Carter LM. Manipulating the glial scar: chondroitinase ABC as a therapy for spinal 655 
cord injury. Brain Res Bull 2011; 84: 306-16. 656 
 657 
Bradbury EJ, Moon LD, Popat RJ, King VR, Bennett GS, Patel PN, et al. Chondroitinase ABC 658 
promotes functional recovery after spinal cord injury. Nature 2002; 416: 636-40. 659 
 660 
Cafferty WB, Bradbury EJ, Lidierth M, Jones M, Duffy PJ, Pezet S, et al. Chondroitinase ABC-661 
mediated plasticity of spinal sensory function, J. Neurosci 2008; 28: 11998–12009. 662 
 663 
Combrisson H, Cotard JP. Utility of urodynamic testing in the diganosis of urinary incontinence 664 
in dogs. Rec Med Vet. 1989; 165: 839-46. 665 
 666 
Crespo D, Asher RA, Lin R, Rhodes KE, Fawcett JW. How does chondroitinase promote 667 
functional recovery in the damaged CNS? Exp. Neurol 2007; 206: 159-171 668 
 669 
da Costa RC, Poma R, Parent JM, Partlow G, Monteith G. Correlation of motor evoked potentials 670 
with magnetic resonance imaging and neurologic findings in Doberman Pinschers with and 671 
without signs of cervical spondylomyelopathy. Am J Vet Res 2006; 67: 1613-20. 672 
 673 
Fawcett JW, Curt A, Steeves JD, Coleman WP, Tuszynski MH, Lammertse D, et al. Guidelines 674 
for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: spontaneous 675 
recovery after spinal cord injury and statistical power needed for therapeutic clinical trials. Spinal 676 
Cord 2007; 45: 190-205.  677 
 678 
23 
 
Frank SA, Wilson R, Holloway RG, Zimmerman C, Peterson DR, Kieburtz K, et al. 679 
Ethics of sham surgery: perspective of patients. Mov Disord 2008; 23: 63-8. 680 
 681 
Freedman MS, Bar-Or A, Atkins HL, Karussis D, Frassoni F, Lazarus H, et al. MSCT Study 682 
Group. The therapeutic potential of mesenchymal stem cell transplantation as a treatment for 683 
multiple sclerosis: consensus report of the International MSCT Study Group. Mult Scler 2010 684 
16: 503-10. 685 
 686 
Garcia-Alias G, Barkhuysen S, Buckle M, Fawcett JW. Chondroitinase ABC treatment opens a 687 
window of opportunity for task-specific rehabilitation. Nat Neurosci 2009; 12: 1145–1151. 688 
 689 
Gallucci A, Dragone L, Menchetti M, Gagliardo T, Pietra M, Cardinali M, et al. Acquisition of 690 
involuntary spinal locomotion (spinal walking) in dogs with irreversible thoracolumbar spinal 691 
cord lesion: 81 dogs. J Vet Intern Med 2017; 31: 492-497. 692 
 693 
Granger N, Blamires H, Franklin RJ, Jeffery ND. Autologous olfactory mucosal cell transplants 694 
in clinical spinal cord injury: a randomized double-blinded trial in a canine translational model. 695 
Brain 2012; 135: 3227-37. 696 
 697 
Griffiths IR. Spinal cord injuries: a pathological study of naturally occurring lesions in the dog and 698 
cat. J Comp Pathol 1978 88: 303-15. 699 
 700 
Gutierrez-Quintana R, Edgar J, Wessmann A, Cherubini GB, Penderis J. The cutaneous trunci 701 
reflex for localising and grading thoracolumbar spinal cord injuries in dogs. J Small Anim Pract 702 
2012; 53: 470-5. 703 
 704 
Hamilton L, Franklin RJ, Jeffery ND. Development of a universal measure of quadrupedal 705 
forelimb-hindlimb coordination using digital motion capture and computerised analysis. BMC 706 
Neurosci 2007; 8:77. 707 
 708 
24 
 
Harris RL, Cundiff GW, Theofrastous JP, Bump RC. Bladder compliance in neurologically intact 709 
women. Neurourol Urodyn. 1996; 15: 483-8. 710 
 711 
Jefferson SC, Tester NJ, Howland DR. Chondroitinase ABC promotes recovery of adaptive limb 712 
movements and enhances axonal growth caudal to a spinal hemisection. J Neurosci 2011; 31: 713 
5710-20. 714 
 715 
Kwon BK, Okon E, Hillyer J, Mann C, Baptiste D, Weaver LC, et al. A systematic review of non-716 
invasive pharmacologic neuroprotective treatments for acute spinal cord injury. J Neurotrauma 717 
2011; 28: 1545-88.  718 
 719 
Kwon BK, Soril LJ, Bacon M, Beattie MS, Blesch A, Bresnahan JC, et al. Demonstrating efficacy 720 
in preclinical studies of cellular therapies for spinal cord injury - how much is enough? Exp Neurol 721 
2013; 248: 30-44. 722 
 723 
Kwon BK, Streijger F, Hill CE, Anderson AJ, Bacon M, Beattie MS, et al. Large animal and 724 
primate models of spinal cord injury for the testing of novel therapies. Exp Neurol 2015; 269: 154-725 
68.   726 
 727 
Lankhorst AJ, ter Laak MP, van Laar TJ, van Meeteren NL, de Groot JC, Schrama LH, et al. 728 
Effects of enriched housing on functional recovery after spinal cord contusive injury in the 729 
adult rat. J Neurotrauma  2001; 18: 203-15. 730 
 731 
Lee H, McKeon RJ, Bellamkonda R. Sustained delivery of thermostabilized chABC enhances 732 
axonal sprouting and functional recovery after spinal cord injury. Proc Natl Acad Sci U S A 2010; 733 
107: 3340-5.  734 
 735 
Levine JM, Levine GJ, Porter BF, Topp K, Noble-Haeusslein LJ. Naturally occurring disk 736 
herniation in dogs: an opportunity for pre-clinical spinal cord injury research. 737 
J Neurotrauma 2011; 28: 675-88. 738 
 739 
25 
 
Lin R, Kwok D, Crespo D, Fawcett JW. Chondroitinase ABC has a lasting effect on chondroitin 740 
sulphate glycosaminoglycan content in the injured rat brain. J Neurochem 2008; 104: 400-408.  741 
 742 
Massey JM, Hubscher CH, Wagoner MR, Decker JA, Amps J, Silver J, et al. Chondroitinase ABC 743 
digestion of the perineuronal net promotes functional collateral sprouting in the cuneate nucleus 744 
after cervical spinal cord injury J. Neurosci 2006; 26: 4406-4414 745 
 746 
Metz GA, Curt A, van de Meent H, Klusman I, Schwab ME, Dietz V. Validation of the weight-747 
drop contusion model in rats: a comparative study of human spinal cord injury. J Neurotrauma 748 
2000; 17: 1-17. 749 
 750 
Moore SA, Granger N, Olby NJ, Spitzbarth I, Jeffery ND, Tipold A, et al. Targeting translational 751 
successes through CANSORT-SCI: Using pet dogs to identify effective treatments for spinal cord 752 
injury. J Neurotrauma 2017; 34: 2007-18. 753 
 754 
Nashmi R, Imamura H, Tator CH, Fehlings MG. Serial recording of somatosensory and 755 
myoelectric motor evoked potentials: role in assessing functional recovery after graded spinal cord 756 
injury in the rat. J Neurotrauma 1997; 14: 151-9. 757 
 758 
Nollet H, Van Ham L, Deprez P, Vanderstraeten G. Transcranial magnetic stimulation: review of 759 
the technique, basic principles and applications. Vet J 2003; 166: 28-42. 760 
 761 
Poncelet L, Michaux C, Balligand M. Somatosensory potentials in dogs with naturally acquired 762 
thoracolumbar spinal cord disease. Am J Vet Res 1993; 54: 1935-41.    763 
 764 
Smith PM, Jeffery ND. Histological and ultrastructural analysis of white matter damage after 765 
naturally-occurring spinal cord injury. Brain Pathol 2006 16: 99-109. 766 
 767 
Sylvestre AM, Cockshutt JR, Parent JM, Brooke JD, Holmberg DL, Partlow GD. Magnetic motor 768 
evoked potentials for assessing spinal cord integrity in dogs with intervertebral disc disease. Vet 769 
Surg 1993; 22: 5-10. 770 
26 
 
 771 
Tetzlaff W, Okon EB, Karimi-Abdolrezaee S, Hill CE, Sparling JS, Plemel JR, et al. A systematic 772 
review of cellular transplantation therapies for spinal cord injury. J Neurotrauma 2011; 28: 1611-773 
82. 774 
 775 
Toppercer A, Tetreault JP. Compliance of the bladder: an attempt to establish normal values. 776 
Urology. 1979; 14: 204-5. 777 
 778 
Watzlawick R, Rind J, Sena ES, Brommer B, Zhang T, Kopp MA, et al. Olfactory Ensheathing 779 
Cell Transplantation in Experimental Spinal Cord Injury: Effect size and Reporting Bias of 62 780 
Experimental Treatments: A Systematic Review and Meta-Analysis. PLoS Biol. 2016; 14: 781 
e1002468. 782 
 783 
Wicki A, Ritschard R, Loesch U, Deuster S, Rochlitz C, Mamot C. Large-scale manufacturing of 784 
GMP-compliant anti-EGFR targeted nanocarriers: production of doxorubicin-loaded anti-EGFR-785 
immunoliposomes for a first-in-man clinical trial. Int J Pharm 2015; 484: 8-15. 786 
 787 
Yick LW, Cheung PT, So KF, Wu W. Axonal regeneration of Clarke's neurons beyond the spinal 788 
cord injury scar after treatment with chondroitinase ABC. Exp Neurol 2003; 182: 160–168. 789 
